PMID- 28730848
OWN - NLM
STAT- MEDLINE
DCOM- 20180510
LR  - 20220409
IS  - 1497-0015 (Electronic)
IS  - 0706-7437 (Print)
IS  - 0706-7437 (Linking)
VI  - 62
IP  - 9
DP  - 2017 Sep
TI  - Canadian Treatment Guidelines for Individuals at Clinical High Risk of Psychosis.
PG  - 656-661
LID - 10.1177/0706743717719895 [doi]
AB  - OBJECTIVE: Young people who are at clinical high risk (CHR) of developing 
      psychosis are often help seeking and have significant distress and dysfunction. 
      There are limited guidelines for the assessment and treatment for this 
      population. The aim of this guideline was to develop treatment recommendations 
      for this at-risk group. METHOD: A systematic search was conducted for published 
      guidelines for CHR. All current guidelines for schizophrenia were reviewed for 
      treatment guidelines on individuals at CHR. The recommendations adopted were 
      primarily drawn from the European Psychiatric Association (EPA) guidance on the 
      early intervention in clinical high-risk states of psychoses and the 2014 
      National Institute for Health and Care Excellence (NICE) guidelines on the 
      treatment and management of those at CHR for psychosis. RESULTS: After the 
      guideline development process described, 9 recommendations were developed based 
      on the quality of evidence, appropriateness for the Canadian health care system, 
      and clinical expert consensus. CONCLUSIONS: Assessment by an expert in the field 
      was the first recommendation. It was recommended that treatment follow a staged 
      approach with psychological treatments being the first-line treatment and 
      pharmacotherapy reserved for adults, those who did not respond to psychological 
      interventions, and those who had more severe symptoms.
FAU - Addington, Jean
AU  - Addington J
AD  - 1 Department of Psychiatry, Hotchkiss Brain Institute, University of Calgary, 
      Calgary, Alberta.
FAU - Addington, Donald
AU  - Addington D
AD  - 1 Department of Psychiatry, Hotchkiss Brain Institute, University of Calgary, 
      Calgary, Alberta.
FAU - Abidi, Sabina
AU  - Abidi S
AD  - 2 Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia.
FAU - Raedler, Thomas
AU  - Raedler T
AD  - 1 Department of Psychiatry, Hotchkiss Brain Institute, University of Calgary, 
      Calgary, Alberta.
FAU - Remington, Gary
AU  - Remington G
AD  - 3 Department of Psychiatry and Psychological Clinical Science, University of 
      Toronto, Toronto, Ontario.
AD  - 4 Schizophrenia Division, Centre for Addiction and Mental Health, Toronto, 
      Ontario.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170721
PL  - United States
TA  - Can J Psychiatry
JT  - Canadian journal of psychiatry. Revue canadienne de psychiatrie
JID - 7904187
SB  - IM
MH  - Canada
MH  - *Disease Susceptibility
MH  - Humans
MH  - Practice Guidelines as Topic/*standards
MH  - Psychotic Disorders/*therapy
PMC - PMC5593244
OTO - NOTNLM
OT  - clinical high risk
OT  - guidelines
OT  - schizophrenia
OT  - treatment
COIS- Declaration of Conflicting Interests: The author(s) declared no potential 
      conflicts of interest with respect to the research, authorship, and/or 
      publication of this article.
EDAT- 2017/07/22 06:00
MHDA- 2018/05/11 06:00
PMCR- 2018/03/01
CRDT- 2017/07/22 06:00
PHST- 2017/07/22 06:00 [pubmed]
PHST- 2018/05/11 06:00 [medline]
PHST- 2017/07/22 06:00 [entrez]
PHST- 2018/03/01 00:00 [pmc-release]
AID - 10.1177_0706743717719895 [pii]
AID - 10.1177/0706743717719895 [doi]
PST - ppublish
SO  - Can J Psychiatry. 2017 Sep;62(9):656-661. doi: 10.1177/0706743717719895. Epub 
      2017 Jul 21.